These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 27695636)

  • 1. Combination Therapy of Gefitinib and Korean Herbal Medicines Could be a Beneficial Option for Patients with Non-Small-Cell Lung Cancer.
    Lee K; Kim YS; Son CG; Cho JH; Yoo HS; Lee J; Ryu J; Lee N
    J Pharmacopuncture; 2016 Sep; 19(3):259-263. PubMed ID: 27695636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective case-control study.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ
    Complement Ther Med; 2014 Dec; 22(6):1010-8. PubMed ID: 25453521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fuzheng Kang'ai decoction combined with gefitinib in advanced non-small cell lung cancer patients with epidermal growth factor receptor mutations: study protocol for a randomized controlled trial.
    Yang XB; Wu WY; Long SQ; Deng H; Pan ZQ; He WF; Zhou YS; Liao GY; Li QP; Xiao SJ; Cai JZ
    Trials; 2015 Apr; 16():146. PubMed ID: 25873045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case of Stage IV Non-Small Cell Lung Cancer Treated with Korean Medicine Therapy Alone.
    Lee DH; Seong S; Kim SS; Han JB
    Case Rep Oncol; 2013; 6(3):574-8. PubMed ID: 24348396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mutation of the epidermal growth factor receptor gene and its impact on the efficacy of gefitinib in advanced non-small cell lung cance.
    Li XN; Qiu D; Pan X; Hou XX
    Int J Clin Exp Med; 2015; 8(4):5397-405. PubMed ID: 26131116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial.
    Moore AM; Einhorn LH; Estes D; Govindan R; Axelson J; Vinson J; Breen TE; Yu M; Hanna NH
    Lung Cancer; 2006 Apr; 52(1):93-7. PubMed ID: 16488055
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effectiveness of gefitinib on spinal metastases of lung cancer - report of two cases -.
    Zukawa M; Nakano M; Hirano N; Mizuhashi K; Kanamori M
    Asian Spine J; 2008 Dec; 2(2):109-13. PubMed ID: 20404966
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical observation of gefitinib as a first-line therapy in sixty-eight patients with advanced NSCLC.
    Gao Z; Han B; Wang H; Shi C; Xiong L; Gu A
    Oncol Lett; 2012 May; 3(5):1064-1068. PubMed ID: 22783392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-World Data on Prognostic Factors for Overall Survival in EGFR Mutation-Positive Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Gefitinib.
    Yao ZH; Liao WY; Ho CC; Chen KY; Shih JY; Chen JS; Lin ZZ; Lin CC; Chih-Hsin Yang J; Yu CJ
    Oncologist; 2017 Sep; 22(9):1075-1083. PubMed ID: 28507206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Evaluation of gefitinib plus radiotherapy in non-small-cell lung cancer patients with brain metastases].
    Fu H; Zhang XL; Xiao Y; Liu XJ; Long C; Hu YD
    Zhonghua Yi Xue Za Zhi; 2012 Feb; 92(8):524-7. PubMed ID: 22490154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase II trial of gefitinib monotherapy in chemotherapy-naïve patients of 75 years or older with advanced non-small cell lung cancer.
    Ebi N; Semba H; Tokunaga SJ; Takayama K; Wataya H; Kuraki T; Yamamoto H; Akamine SJ; Okamoto I; Nakanishi Y;
    J Thorac Oncol; 2008 Oct; 3(10):1166-71. PubMed ID: 18827614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status.
    Chang GC; Chen KC; Yang TY; Yin MC; Lin CP; Kuo BI; Hsu JY
    Invest New Drugs; 2005 Jan; 23(1):73-7. PubMed ID: 15528983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tolerability and Outcomes of First-Line Pemetrexed-Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in Korean Patients with Advanced Nonsquamous Non-small Cell Lung Cancer: A Post Hoc Descriptive Subgroup Analysis of a Randomized, Phase 3 Trial.
    Kang JH; Ahn MJ; Kim DW; Cho EK; Kim JH; Shin SW; Wang X; Kim JS; Orlando M; Park K
    Cancer Res Treat; 2016 Apr; 48(2):458-64. PubMed ID: 26511807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid bone repair in a patient with lung cancer metastases to the spine using a novel herbal medicine: A case report.
    Pu R; Zhao Q; Li Z; Zhang L; Luo X; Zeren Y; Yu C; Li X
    Oncol Lett; 2016 Sep; 12(3):2023-2027. PubMed ID: 27602132
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gefitinib therapy for non-small cell lung cancer.
    Birnbaum A; Ready N
    Curr Treat Options Oncol; 2005 Jan; 6(1):75-81. PubMed ID: 15610717
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlotinib and gefitinib for treating non-small cell lung cancer that has progressed following prior chemotherapy (review of NICE technology appraisals 162 and 175): a systematic review and economic evaluation.
    Greenhalgh J; Bagust A; Boland A; Dwan K; Beale S; Hockenhull J; Proudlove C; Dundar Y; Richardson M; Dickson R; Mullard A; Marshall E
    Health Technol Assess; 2015 Jun; 19(47):1-134. PubMed ID: 26134145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gefitinib in non-small cell lung cancer.
    Tamura K; Fukuoka M
    Expert Opin Pharmacother; 2005 Jun; 6(6):985-93. PubMed ID: 15952926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized Phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy.
    Lee DH; Park K; Kim JH; Lee JS; Shin SW; Kang JH; Ahn MJ; Ahn JS; Suh C; Kim SW
    Clin Cancer Res; 2010 Feb; 16(4):1307-14. PubMed ID: 20145166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy.
    Kim ST; Lee J; Kim JH; Won YW; Sun JM; Yun J; Park YH; Ahn JS; Park K; Ahn MJ
    Cancer; 2010 Jun; 116(12):3025-33. PubMed ID: 20564408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706).
    Zhang Z; Luo F; Zhang Y; Ma Y; Hong S; Yang Y; Fang W; Huang Y; Zhang L; Zhao H
    Cancer Commun (Lond); 2019 Nov; 39(1):69. PubMed ID: 31699150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.